1. Home
  2. HYFM vs GANX Comparison

HYFM vs GANX Comparison

Compare HYFM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hydrofarm Holdings Group Inc.

HYFM

Hydrofarm Holdings Group Inc.

HOLD

Current Price

$1.72

Market Cap

11.2M

Sector

Industrials

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$3.14

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYFM
GANX
Founded
1977
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
159.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
HYFM
GANX
Price
$1.72
$3.14
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
99.7K
2.2M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$146,443,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$1.41
52 Week High
$7.50
$4.34

Technical Indicators

Market Signals
Indicator
HYFM
GANX
Relative Strength Index (RSI) 42.91 48.75
Support Level $1.68 $2.14
Resistance Level $2.74 $3.45
Average True Range (ATR) 0.32 0.50
MACD 0.01 -0.14
Stochastic Oscillator 17.07 45.46

Price Performance

Historical Comparison
HYFM
GANX

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: